메뉴 건너뛰기




Volumn 99, Issue 6, 2014, Pages 956-964

Clinical and genetic predictors of prognosis in myelodysplastic syndromes

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELL SURFACE MARKER; GENETIC MARKER;

EID: 84901711863     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.085217     Document Type: Review
Times cited : (89)

References (60)
  • 1
    • 80053192528 scopus 로고    scopus 로고
    • Classification and prognostic evaluation of myelodysplastic syndromes
    • Cazzola M, Della Porta MG, Travaglino E, Malcovati L. Classification and prognostic evaluation of myelodysplastic syndromes. Semin Oncol. 2011;38(5):627-34.
    • (2011) Semin Oncol. , vol.38 , Issue.5 , pp. 627-634
    • Cazzola, M.1    Della Porta, M.G.2    Travaglino, E.3    Malcovati, L.4
  • 2
    • 0030897009 scopus 로고    scopus 로고
    • International scoring system for evaluating prognosis in myelodysplastic syndromes
    • Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89 (6):2079-88.
    • (1997) Blood. , vol.89 , Issue.6 , pp. 2079-2088
    • Greenberg, P.1    Cox, C.2    LeBeau, M.M.3    Fenaux, P.4    Morel, P.5    Sanz, G.6
  • 4
    • 84888240132 scopus 로고    scopus 로고
    • Diagnosis and treatment of primary myelodysplastic syndromes in adults: Recommendations from the European LeukemiaNet
    • Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122(17):2943-64.
    • (2013) Blood. , vol.122 , Issue.17 , pp. 2943-2964
    • Malcovati, L.1    Hellstrom-Lindberg, E.2    Bowen, D.3    Ades, L.4    Cermak, J.5    Del Canizo, C.6
  • 5
    • 0036786901 scopus 로고    scopus 로고
    • The World Health Organization (WHO) classification of the myeloid neoplasms
    • Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-302.
    • (2002) Blood. , vol.100 , Issue.7 , pp. 2292-2302
    • Vardiman, J.W.1    Harris, N.L.2    Brunning, R.D.3
  • 6
    • 70349256226 scopus 로고    scopus 로고
    • The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes
    • Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
    • (2009) Blood. , vol.114 , Issue.5 , pp. 937-951
    • Vardiman, J.W.1    Thiele, J.2    Arber, D.A.3    Brunning, R.D.4    Borowitz, M.J.5    Porwit, A.6
  • 7
    • 84866621729 scopus 로고    scopus 로고
    • Revised international prognostic scoring system for myelodysplastic syndromes
    • Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454-65.
    • (2012) Blood. , vol.120 , Issue.12 , pp. 2454-2465
    • Greenberg, P.L.1    Tuechler, H.2    Schanz, J.3    Sanz, G.4    Garcia-Manero, G.5    Sole, F.6
  • 8
    • 84901725129 scopus 로고    scopus 로고
    • An Updated Risk Model That Improves Prognostic Forecasting in Myelodysplastic Syndromes
    • Steensma DP. An Updated Risk Model That Improves Prognostic Forecasting in Myelodysplastic Syndromes. The Hematologist. 2012;9(6):10.
    • (2012) The Hematologist. , vol.9 , Issue.6 , pp. 10
    • Steensma, D.P.1
  • 9
    • 84887628183 scopus 로고    scopus 로고
    • P-113 Revised International Prognostic Scoring System (IPSS-R) for primary treated myelodysplastic syndromes (MDS) patients: A report from the IWG-PM
    • Sekeres M, Ades L, Tuechler H, Sanz G, Levis A, Malcovati L, et al. P-113 Revised International Prognostic Scoring System (IPSS-R) for primary treated myelodysplastic syndromes (MDS) patients: A report from the IWG-PM. Leuk Res. 2013;37 Suppl 1:S74-S5.
    • (2013) Leuk Res. , vol.37 , Issue.SUPPL. 1 , pp. 74-75
    • Sekeres, M.1    Ades, L.2    Tuechler, H.3    Sanz, G.4    Levis, A.5    Malcovati, L.6
  • 10
    • 84901698428 scopus 로고    scopus 로고
    • P-104 Outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDS with del(5q) in MDS-003 and MDS-004: A retrospective analysis
    • Sekeres M, Swern A, Fenaux P, Greenberg P, Sanz G, Bennett J, et al. P-104 Outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDS with del(5q) in MDS-003 and MDS-004: a retrospective analysis. Leuk Res. 2013;37(Supplement 1):S69-S70.
    • (2013) Leuk Res. , vol.37 , Issue.SUPPL. 1
    • Sekeres, M.1    Swern, A.2    Fenaux, P.3    Greenberg, P.4    Sanz, G.5    Bennett, J.6
  • 11
    • 84879406390 scopus 로고    scopus 로고
    • Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
    • Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, et al. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Am J Hematol. 2013;88(7):566-70.
    • (2013) Am J Hematol. , vol.88 , Issue.7 , pp. 566-570
    • Mishra, A.1    Corrales-Yepez, M.2    Ali, N.A.3    Kharfan-Dabaja, M.4    Padron, E.5    Zhang, L.6
  • 12
    • 84890560117 scopus 로고    scopus 로고
    • Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study
    • Neukirchen J, Lauseker M, Blum S, Giagounidis A, Lübbert M, Martino S, et al. Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study. Leuk Res. 2014;38(1):57-64.
    • (2014) Leuk Res. , vol.38 , Issue.1 , pp. 57-64
    • Neukirchen, J.1    Lauseker, M.2    Blum, S.3    Giagounidis, A.4    Lübbert, M.5    Martino, S.6
  • 13
    • 84873997950 scopus 로고    scopus 로고
    • Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine
    • Breccia M, Salaroli A, Loglisci G, Alimena G. Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine. Ann Hematol. 2013;92(3):411-2.
    • (2013) Ann Hematol. , vol.92 , Issue.3 , pp. 411-412
    • Breccia, M.1    Salaroli, A.2    Loglisci, G.3    Alimena, G.4
  • 14
    • 84890467356 scopus 로고    scopus 로고
    • Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database
    • Voso MT, Fenu S, Latagliata R, Buccisano F, Piciocchi A, Aloe-Spiriti MA, et al. Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J Clin Oncol. 2013;31 (21):2671-7.
    • (2013) J Clin Oncol. , vol.31 , Issue.21 , pp. 2671-2677
    • Voso, M.T.1    Fenu, S.2    Latagliata, R.3    Buccisano, F.4    Piciocchi, A.5    Aloe-Spiriti, M.A.6
  • 15
    • 80053186861 scopus 로고    scopus 로고
    • Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)
    • Malcovati L, Della Porta MG, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 2011;96 (10):1433-40.
    • (2011) Haematologica. , vol.96 , Issue.10 , pp. 1433-1440
    • Malcovati, L.1    Della Porta, M.G.2    Strupp, C.3    Ambaglio, I.4    Kuendgen, A.5    Nachtkamp, K.6
  • 16
  • 17
    • 84866749552 scopus 로고    scopus 로고
    • Validation of a prognostic model and the impact of mutations in patients with lowerrisk myelodysplastic syndromes
    • Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, et al. Validation of a prognostic model and the impact of mutations in patients with lowerrisk myelodysplastic syndromes. J Clin Oncol. 2012;30(27):3376-82.
    • (2012) J Clin Oncol. , vol.30 , Issue.27 , pp. 3376-3382
    • Bejar, R.1    Stevenson, K.E.2    Caughey, B.A.3    Abdel-Wahab, O.4    Steensma, D.P.5    Galili, N.6
  • 20
    • 84880263477 scopus 로고    scopus 로고
    • Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes
    • Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013;27(7):1504-10.
    • (2013) Leukemia. , vol.27 , Issue.7 , pp. 1504-1510
    • Patnaik, M.M.1    Padron, E.2    LaBorde, R.R.3    Lasho, T.L.4    Finke, C.M.5    Hanson, C.A.6
  • 21
    • 84877069358 scopus 로고    scopus 로고
    • Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia
    • Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, Della Porta MG, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121 (15):3005-15.
    • (2013) Blood. , vol.121 , Issue.15 , pp. 3005-3015
    • Such, E.1    Germing, U.2    Malcovati, L.3    Cervera, J.4    Kuendgen, A.5    Della Porta, M.G.6
  • 22
    • 53149113768 scopus 로고    scopus 로고
    • Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
    • Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113(6):1351-61.
    • (2008) Cancer. , vol.113 , Issue.6 , pp. 1351-1361
    • Kantarjian, H.1    O'Brien, S.2    Ravandi, F.3    Cortes, J.4    Shan, J.5    Bennett, J.M.6
  • 23
    • 84860682437 scopus 로고    scopus 로고
    • Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome
    • Komrokji RS, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Fields T, et al. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. Cancer. 2012;118(10):2659-64.
    • (2012) Cancer. , vol.118 , Issue.10 , pp. 2659-2664
    • Komrokji, R.S.1    Corrales-Yepez, M.2    Ali, N.A.3    Kharfan-Dabaja, M.4    Padron, E.5    Fields, T.6
  • 24
    • 78751705026 scopus 로고    scopus 로고
    • Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients
    • Breccia M, Federico V, Latagliata R, Mercanti C, D'Elia GM, Cannella L, et al. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. Leuk Res. 2011;35(2):159-62.
    • (2011) Leuk Res. , vol.35 , Issue.2 , pp. 159-162
    • Breccia, M.1    Federico, V.2    Latagliata, R.3    Mercanti, C.4    D'Elia, G.M.5    Cannella, L.6
  • 25
    • 79952346792 scopus 로고    scopus 로고
    • Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome
    • Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011;96(3):441-9.
    • (2011) Haematologica. , vol.96 , Issue.3 , pp. 441-449
    • Della Porta, M.G.1    Malcovati, L.2    Strupp, C.3    Ambaglio, I.4    Kuendgen, A.5    Zipperer, E.6
  • 26
    • 79957943933 scopus 로고    scopus 로고
    • Association of comorbidities with overall survival in myelodysplastic syndrome: Development of a prognostic model
    • Naqvi K, Garcia-Manero G, Sardesai S, Oh J, Vigil CE, Pierce S, et al. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol. 2011;29 (16):2240-6.
    • (2011) J Clin Oncol. , vol.29 , Issue.16 , pp. 2240-2246
    • Naqvi, K.1    Garcia-Manero, G.2    Sardesai, S.3    Oh, J.4    Vigil, C.E.5    Pierce, S.6
  • 27
    • 84879441095 scopus 로고    scopus 로고
    • How I assess comorbidities before hematopoietic cell transplantation
    • Sorror ML. How I assess comorbidities before hematopoietic cell transplantation. Blood. 2013;121(15):2854-63.
    • (2013) Blood. , vol.121 , Issue.15 , pp. 2854-2863
    • Sorror, M.L.1
  • 28
    • 23944440464 scopus 로고    scopus 로고
    • Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT
    • Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-9.
    • (2005) Blood. , vol.106 , Issue.8 , pp. 2912-2919
    • Sorror, M.L.1    Maris, M.B.2    Storb, R.3    Baron, F.4    Sandmaier, B.M.5    Maloney, D.G.6
  • 29
    • 70449464264 scopus 로고    scopus 로고
    • Comorbidity as prognostic variable in MDS: Comparative evaluation of the HCTCI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group
    • Sperr WR, Wimazal F, Kundi M, Baumgartner C, Nosslinger T, Makrai A, et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCTCI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol. 2010;21(1):114-9.
    • (2010) Ann Oncol. , vol.21 , Issue.1 , pp. 114-119
    • Sperr, W.R.1    Wimazal, F.2    Kundi, M.3    Baumgartner, C.4    Nosslinger, T.5    Makrai, A.6
  • 31
    • 79955945973 scopus 로고    scopus 로고
    • Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies
    • Tiu RV, Gondek LP, O'Keefe CL, Elson P, Huh J, Mohamedali A, et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood. 2011;117(17): 4552-60.
    • (2011) Blood. , vol.117 , Issue.17 , pp. 4552-4560
    • Tiu, R.V.1    Gondek, L.P.2    O'Keefe, C.L.3    Elson, P.4    Huh, J.5    Mohamedali, A.6
  • 32
    • 85027941662 scopus 로고    scopus 로고
    • Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes
    • Thol F, Yun H, Sonntag AK, Damm F, Weissinger EM, Krauter J, et al. Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes. Ann Hematol. 2012;91(8):1221-33.
    • (2012) Ann Hematol. , vol.91 , Issue.8 , pp. 1221-1233
    • Thol, F.1    Yun, H.2    Sonntag, A.K.3    Damm, F.4    Weissinger, E.M.5    Krauter, J.6
  • 33
    • 84873396563 scopus 로고    scopus 로고
    • Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: Position paper of an International Consortium and the European LeukemiaNet Working Group
    • van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, et al. Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leuk Lymphoma. 2013;54(3):472-5.
    • (2013) Leuk Lymphoma. , vol.54 , Issue.3 , pp. 472-475
    • van de Loosdrecht, A.A.1    Ireland, R.2    Kern, W.3    Della Porta, M.G.4    Alhan, C.5    Balleisen, J.S.6
  • 34
    • 84863785114 scopus 로고    scopus 로고
    • Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group
    • Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia. 2012;26(7):1730-41.
    • (2012) Leukemia. , vol.26 , Issue.7 , pp. 1730-1741
    • Westers, T.M.1    Ireland, R.2    Kern, W.3    Alhan, C.4    Balleisen, J.S.5    Bettelheim, P.6
  • 35
    • 84890568873 scopus 로고    scopus 로고
    • Standardizing the initial evaluation for myelodysplastic syndromes
    • Marshall D, Roboz GJ. Standardizing the initial evaluation for myelodysplastic syndromes. Curr Hematol Malig Rep. 2013;8(4): 361-9.
    • (2013) Curr Hematol Malig Rep. , vol.8 , Issue.4 , pp. 361-369
    • Marshall, D.1    Roboz, G.J.2
  • 36
    • 84875910316 scopus 로고    scopus 로고
    • Molecular pathophysiology of myelodysplastic syndromes
    • Lindsley RC, Ebert BL. Molecular pathophysiology of myelodysplastic syndromes. Annu Rev Pathol. 2013;8(1):21-47.
    • (2013) Annu Rev Pathol. , vol.8 , Issue.1 , pp. 21-47
    • Lindsley, R.C.1    Ebert, B.L.2
  • 37
    • 84891301466 scopus 로고    scopus 로고
    • The genetic basis of myelodysplasia and its clinical relevance
    • Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013;122(25):4021-34.
    • (2013) Blood. , vol.122 , Issue.25 , pp. 4021-4034
    • Cazzola, M.1    Della Porta, M.G.2    Malcovati, L.3
  • 39
    • 84888219405 scopus 로고    scopus 로고
    • Clinical and biological implications of driver mutations in myelodysplastic syndromes
    • Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616-27.
    • (2013) Blood. , vol.122 , Issue.22 , pp. 3616-3627
    • Papaemmanuil, E.1    Gerstung, M.2    Malcovati, L.3    Tauro, S.4    Gundem, G.5    Van Loo, P.6
  • 40
    • 84893772765 scopus 로고    scopus 로고
    • Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
    • Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241-7.
    • (2014) Leukemia. , vol.28 , Issue.2 , pp. 241-247
    • Haferlach, T.1    Nagata, Y.2    Grossmann, V.3    Okuno, Y.4    Bacher, U.5    Nagae, G.6
  • 41
    • 84867230100 scopus 로고    scopus 로고
    • Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion
    • Sebaa A, Ades L, Baran-Marzack F, Mozziconacci MJ, Penther D, Dobbelstein S, et al. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes Chromosomes Cancer. 2012;51(12): 1086-92.
    • (2012) Genes Chromosomes Cancer. , vol.51 , Issue.12 , pp. 1086-1092
    • Sebaa, A.1    Ades, L.2    Baran-Marzack, F.3    Mozziconacci, M.J.4    Penther, D.5    Dobbelstein, S.6
  • 43
    • 84901706039 scopus 로고    scopus 로고
    • Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome
    • Volkert S, Kohlmann A, Schnittger S, Kern W, Haferlach T, Haferlach C. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome. Genes Chromosomes Cancer. 2014;3(10):22151.
    • (2014) Genes Chromosomes Cancer. , vol.3 , Issue.10 , pp. 22151
    • Volkert, S.1    Kohlmann, A.2    Schnittger, S.3    Kern, W.4    Haferlach, T.5    Haferlach, C.6
  • 44
    • 84884727942 scopus 로고    scopus 로고
    • Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia
    • Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, et al. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol. 2013;88(10):831-7.
    • (2013) Am J Hematol. , vol.88 , Issue.10 , pp. 831-837
    • Jabbour, E.1    Takahashi, K.2    Wang, X.3    Cornelison, A.M.4    Abruzzo, L.5    Kadia, T.6
  • 46
    • 84878900540 scopus 로고    scopus 로고
    • Clonal diversity of recurrently mutated genes in myelodysplastic syndromes
    • Walter MJ, Shen D, Shao J, Ding L, White BS, Kandoth C, et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia. 2013;27(6):1275-82.
    • (2013) Leukemia. , vol.27 , Issue.6 , pp. 1275-1282
    • Walter, M.J.1    Shen, D.2    Shao, J.3    Ding, L.4    White, B.S.5    Kandoth, C.6
  • 47
    • 79956291339 scopus 로고    scopus 로고
    • TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression
    • Jadersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Gohring G, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011;29(15):1971-9.
    • (2011) J Clin Oncol. , vol.29 , Issue.15 , pp. 1971-1979
    • Jadersten, M.1    Saft, L.2    Smith, A.3    Kulasekararaj, A.4    Pomplun, S.5    Gohring, G.6
  • 48
    • 84885606356 scopus 로고    scopus 로고
    • Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML
    • Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, et al. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013;27(10): 2081-3.
    • (2013) Leukemia. , vol.27 , Issue.10 , pp. 2081-2083
    • Takahashi, K.1    Jabbour, E.2    Wang, X.3    Luthra, R.4    Bueso-Ramos, C.5    Patel, K.6
  • 49
    • 84885657625 scopus 로고    scopus 로고
    • NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes
    • Murphy DM, Bejar R, Stevenson K, Neuberg D, Shi Y, Cubrich C, et al. NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes. Leukemia. 2013;27(10):2077-81.
    • (2013) Leukemia. , vol.27 , Issue.10 , pp. 2077-2081
    • Murphy, D.M.1    Bejar, R.2    Stevenson, K.3    Neuberg, D.4    Shi, Y.5    Cubrich, C.6
  • 51
    • 84893950322 scopus 로고    scopus 로고
    • Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression
    • Hou HA, Kuo YY, Tang JL, Chou WC, Yao M, Lai YJ, et al. Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression. Am J Hematol. 2014;89(2):181-6.
    • (2014) Am J Hematol. , vol.89 , Issue.2 , pp. 181-186
    • Hou, H.A.1    Kuo, Y.Y.2    Tang, J.L.3    Chou, W.C.4    Yao, M.5    Lai, Y.J.6
  • 53
    • 84884982828 scopus 로고    scopus 로고
    • Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression
    • Fernandez-Mercado M, Pellagatti A, Di Genua C, Larrayoz MJ, Winkelmann N, Aranaz P, et al. Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression. Br J Haematol. 2013;163(2):235-9.
    • (2013) Br J Haematol. , vol.163 , Issue.2 , pp. 235-239
    • Fernandez-Mercado, M.1    Pellagatti, A.2    Di Genua, C.3    Larrayoz, M.J.4    Winkelmann, N.5    Aranaz, P.6
  • 54
    • 84878947680 scopus 로고    scopus 로고
    • SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias
    • Damm F, Itzykson R, Kosmider O, Droin N, Renneville A, Chesnais V, et al. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia. 2013;27(6):1401-3.
    • (2013) Leukemia. , vol.27 , Issue.6 , pp. 1401-1403
    • Damm, F.1    Itzykson, R.2    Kosmider, O.3    Droin, N.4    Renneville, A.5    Chesnais, V.6
  • 55
    • 83455234787 scopus 로고    scopus 로고
    • Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
    • Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011;118(24):6239-46.
    • (2011) Blood. , vol.118 , Issue.24 , pp. 6239-6246
    • Malcovati, L.1    Papaemmanuil, E.2    Bowen, D.T.3    Boultwood, J.4    Della Porta, M.G.5    Pascutto, C.6
  • 56
    • 84860767817 scopus 로고    scopus 로고
    • SF3B1 mutations in myelodysplastic syndromes: Clinical associations and prognostic implications
    • Damm F, Thol F, Kosmider O, Kade S, Loffeld P, Dreyfus F, et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia. 2012;26(5):1137-40.
    • (2012) Leukemia. , vol.26 , Issue.5 , pp. 1137-1140
    • Damm, F.1    Thol, F.2    Kosmider, O.3    Kade, S.4    Loffeld, P.5    Dreyfus, F.6
  • 57
    • 84855841586 scopus 로고    scopus 로고
    • SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value
    • Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2012;119(2):569-72.
    • (2012) Blood. , vol.119 , Issue.2 , pp. 569-572
    • Patnaik, M.M.1    Lasho, T.L.2    Hodnefield, J.M.3    Knudson, R.A.4    Ketterling, R.P.5    Garcia-Manero, G.6
  • 58
    • 84858830672 scopus 로고    scopus 로고
    • New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge
    • Schanz J, Tuchler H, Sole F, Mallo M, Luno E, Cervera J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9.
    • (2012) J Clin Oncol. , vol.30 , Issue.8 , pp. 820-829
    • Schanz, J.1    Tuchler, H.2    Sole, F.3    Mallo, M.4    Luno, E.5    Cervera, J.6
  • 59
    • 84873995626 scopus 로고    scopus 로고
    • TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis
    • Kulasekararaj AG, Smith AE, Mian SA, Mohamedali AM, Krishnamurthy P, Lea NC, et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol. 2013; 160(5):660-72.
    • (2013) Br J Haematol. , vol.160 , Issue.5 , pp. 660-672
    • Kulasekararaj, A.G.1    Smith, A.E.2    Mian, S.A.3    Mohamedali, A.M.4    Krishnamurthy, P.5    Lea, N.C.6
  • 60
    • 84884286307 scopus 로고    scopus 로고
    • The impact of the Oncotype Dx breast cancer assay in clinical practice: A systematic review and metaanalysis
    • Carlson JJ, Roth JA. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and metaanalysis. Breast Cancer Res Treat. 2013; 141(1):13-22.
    • (2013) Breast Cancer Res Treat. , vol.141 , Issue.1 , pp. 13-22
    • Carlson, J.J.1    Roth, J.A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.